[A18-81] Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V
Last updated 16.05.2019
Project no.:
A18-81
Commission:
Commission awarded on 22.11.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with chronic lymphocytic leukaemia who have received at least one prior therapy
No adequate implementation of appropriate comparator therapy; added benefit neither proven for patients with 17p deletion or TP53 mutation nor for patients without 17p deletion or TP53 mutation
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-39 | Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-35 | Venetoclax (chronic lymphocytic leukaemia; combination with rituximab) - Addendum to Commission A18-81 | Commission completed |
| A18-82 | Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G16-14 | Venetoclax (chronic lymphocytic leukaemia) – Assessment according to § 35a (para. 1, sentence 10) Social Code Book V | Commission completed |
| A21-82 | Venetoclax (acute myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-05-16 A G-BA decision was published.